Diadema Partners LP Nektar Therapeutics Transaction History
Diadema Partners LP
- $383 Billion
- Q1 2025
A detailed history of Diadema Partners LP transactions in Nektar Therapeutics stock. As of the latest transaction made, Diadema Partners LP holds 678,200 shares of NKTR stock, worth $15.6 Million. This represents 0.12% of its overall portfolio holdings.
Number of Shares
678,200
Previous 698,919
2.96%
Holding current value
$15.6 Million
Previous $650 Million
29.05%
% of portfolio
0.12%
Previous 0.28%
Shares
1 transactions
Others Institutions Holding NKTR
# of Institutions
119Shares Held
106MCall Options Held
1.18MPut Options Held
64.6K-
Black Rock Inc. New York, NY15.2MShares$349 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.3MShares$284 Million0.0% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT7.79MShares$180 Million0.24% of portfolio
-
Eventide Asset Management, LLC Boston, MA6.65MShares$153 Million0.1% of portfolio
-
Primecap Management CO Pasadena, CA5.35MShares$123 Million0.0% of portfolio
About NEKTAR THERAPEUTICS
- Ticker NKTR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 187,404,992
- Market Cap $4.32B
- Description
- Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...